创新医疗(002173) - 2023 Q3 - 季度财报

Financial Performance - The company's revenue for Q3 2023 was ¥201,840,624.54, representing a decrease of 1.53% compared to the same period last year[4] - The net profit attributable to shareholders for Q3 2023 was -¥10,760,983.37, a decline of 130.56% year-on-year[5] - The net profit attributable to shareholders after deducting non-recurring gains and losses was -¥13,403,792.46, a significant decrease of 491.95% compared to the previous year[4] - The basic earnings per share for Q3 2023 was -¥0.0241, down 130.51% from the previous year[5] - Net loss for Q3 2023 was CNY 14,256,798.12, compared to a net loss of CNY 13,120,718.90 in Q3 2022, reflecting a decline in profitability[20] - The company reported a gross profit margin of approximately -1.0% for Q3 2023, down from a margin of approximately -0.7% in Q3 2022[19] - Basic and diluted earnings per share for Q3 2023 were both -0.0319, compared to -0.0289 in Q3 2022, indicating a worsening in per-share performance[20] Cash Flow and Liquidity - The operating cash flow for the year-to-date period reached ¥28,517,936.69, an increase of 140.24% compared to the same period last year[9] - The company reported a significant increase in cash flow from operating activities due to the resolution of previous payment issues[9] - Cash generated from operating activities was CNY 601,347,530.39 in Q3 2023, compared to CNY 473,638,710.09 in Q3 2022, indicating improved cash flow[21] - Total cash inflow from operating activities reached ¥618,576,032.70, up from ¥497,825,765.23 in the same period last year, reflecting a growth of approximately 24.2%[22] - The net cash flow from operating activities for Q3 2023 was ¥28,517,936.69, a significant improvement compared to a net outflow of ¥70,873,010.45 in Q3 2022, indicating a turnaround in operational performance[22] - The company reported a net decrease in cash and cash equivalents of ¥37,420,766.85 for the quarter, contrasting with a net increase of ¥407,793,014.12 in the previous year[23] - The ending balance of cash and cash equivalents was ¥620,884,321.32, slightly down from ¥633,503,859.71 at the end of Q3 2022[23] Assets and Liabilities - The total assets at the end of the reporting period were ¥2,290,951,408.02, a decrease of 2.08% from the end of the previous year[5] - Current assets totaled CNY 756,582,965.10, down from CNY 771,647,870.32 at the start of the year, primarily due to a decrease in cash and inventory[15] - Non-current assets totaled CNY 1,534,368,442.92, slightly down from CNY 1,568,014,889.21[16] - The total liabilities decreased to CNY 399,554,956.92 in Q3 2023 from CNY 434,414,157.60 in Q3 2022, a reduction of approximately 8.0%[19] - The total equity attributable to shareholders was ¥1,890,502,934.39, down 0.73% from the previous year[5] - The company's total equity attributable to shareholders was CNY 1,890,502,934.39, slightly down from CNY 1,904,313,052.88 in the previous year[19] Shareholder Information - The top 10 shareholders hold a significant portion of the company's shares, with the largest shareholder owning 77,616,997 shares[12] Future Plans and Strategies - The company is focusing on expanding its market presence and developing new technologies[14] - The company has plans for future product launches and strategic acquisitions to enhance growth[14] - The company plans to focus on market expansion and new product development to improve future performance[19] Audit and Reporting - The company has not undergone an audit for the Q3 2023 report, which may affect the perception of financial reliability[24] - The company’s board of directors released the Q3 report on October 26, 2023, indicating timely communication of financial performance[25]